Omega-3 fatty acids reduce hepatic steatosis and consequently attenuate ischemia-reperfusion injury following partial hepatectomy in rats

Digestive and Liver Disease

Volumn 43, Issue 12, 2011, Pages 984-990

  Marsman, Hendrik A ^a   Heger, Michal ^a   Kloek, Jaap J ^a   Nienhuis, Syert L ^a   ten Kate, Fiebo J W ^a   Van Gulik, Thomas M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Hepatic steatosis; Ischemia reperfusion injury; Omega 3 fatty acids

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLINE; LIPID; METHIONINE; OMEGA 3 FATTY ACID; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DIET; DISEASE SEVERITY; FATTY LIVER; HISTOLOGY; LIVER ISCHEMIA; LIVER REGENERATION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; NONHUMAN; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; STANDARD; WEIGHT REDUCTION;

ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANIMALS; CHOLINE DEFICIENCY; DIETARY SUPPLEMENTS; FATTY ACIDS, MONOUNSATURATED; FATTY ACIDS, OMEGA-3; FATTY LIVER; HEPATECTOMY; LIVER; MALE; METHIONINE; OXIDATIVE STRESS; RATS; RATS, WISTAR; REPERFUSION INJURY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 81155162481     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.07.009     Document Type: Article

References (35)

1. Clavien P.A., Petrowsky H., DeOliveira M.L., et al. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007, 356:1545-1559.
2. Vetelainen R., van Vliet A., Gouma D.J., et al. Steatosis as a risk factor in liver surgery. Ann Surg 2007, 245:20-30.
3. de Meijer V., Kalish B.T., Puder M., et al. Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg 2010, 97:1331-1339.
4. van Gulik T.M., de Graaf W., Dinant S., et al. Vascular occlusion techniques during liver resection. Dig Surg 2007, 24:274-281.
5. Jaeschke H., Lemasters J.J. Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology 2003, 125:1246-1257.
6. Selzner M., Rudiger H.A., Sindram D., et al. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology 2000, 32:1280-1288.
7. Pessayre D., Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005, 42:928-940.
8. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
9. Lin H.Z., Yang S.Q., Chuckaree C., et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000, 6:998-1003.
10. Pessayre D., Mansouri A., Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2002, 282:G193-G199.
11. Duvnjak M., Tomasic V., Gomercic M., et al. Therapy of nonalcoholic fatty liver disease: current status. J Physiol Pharmacol 2009, 60(Suppl. 7):57-66.
12. Nakamuta M., Morizono S., Soejima Y., et al. Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Transplantation 2005, 80:608-612.
13. Levy J.R., Clore J.N., Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 2004, 39:608-616.
14. Alwayn I.P., Gura K., Nose V., et al. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res 2005, 57:445-452.
15. Sekiya M., Yahagi N., Matsuzaka T., et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003, 38:1529-1539.
16. El-Badry A.M., Moritz W., Contaldo C., et al. Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids. Hepatology 2007, 45:855-863.
17. Marsman H.A., Heger M., Kloek J.J., et al. Reversal of hepatic steatosis by omega-3 fatty acids measured non-invasively by (1) H-magnetic resonance spectroscopy in a rat model. J Gastroenterol Hepatol 2011, 26:356-363.
18. Vetelainen R., Bennink R.J., van Vliet A.K., et al. Mild steatosis impairs functional recovery after liver resection in an experimental model. Br J Surg 2007, 94:1002-1008.
19. Vetelainen R.L., Bennink R.J., de Bruin K., et al. Hepatobiliary function assessed by 99mTc-mebrofenin cholescintigraphy in the evaluation of severity of steatosis in a rat model. Eur J Nucl Med Mol Imaging 2006, 33:1107-1114.
20. Kloek J.J., Marsman H.A., van Vliet A.K., et al. Biliary drainage attenuates postischemic reperfusion injury in the cholestatic rat liver. Surgery 2008, 144:22-31.
21. Kleiner D.E., Brunt E.M., van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
22. 1H-magnetic resonance spectroscopy. J Magn Reson Imaging 2010, 32:148-154.
23. van Veen S.Q., Dinant S., van Vliet A.K., et al. Alkaline phosphatase reduces hepatic and pulmonary injury in liver ischaemia-reperfusion combined with partial resection. Br J Surg 2006, 93:448-456.
24. Yadav S.S., Gao W., Harland R.C., et al. A new and simple technique of total hepatic ischemia in the mouse. Transplantation 1998, 65:1433-1436.
25. Marsman W.A., Wiesner R.H., Rodriguez L., et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996, 62:1246-1251.
26. de G.W., Heger M., Spruijt O., et al. Quantitative assessment of liver function after ischemia-reperfusion injury and partial hepatectomy in rats. J Surg Res 2010, 10.1016/j.jss.2010.06.038.
27. Giakoustidis D., Papageorgiou G., Iliadis S., et al. Intramuscular administration of very high dose of alpha-tocopherol protects liver from severe ischemia/reperfusion injury. World J Surg 2002, 26:872-877.
28. Oliveira C.P., Gayotto L.C., Tatai C., et al. Vitamin C and vitamin E in prevention of nonalcoholic fatty liver disease (NAFLD) in choline deficient diet fed rats. Nutr J 2003, 2:9.
29. Simopoulos A.P. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 2002, 56:365-379.
30. Araya J., Rodrigo R., Videla L.A., et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004, 106:635-643.
31. Puri P., Baillie R.A., Wiest M.M., et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46:1081-1090.
32. Iwasaki W., Kume M., Kudo K., et al. Changes in the fatty acid composition of the liver with the administration of N-3 polyunsaturated fatty acids and the effects on warm ischemia/reperfusion injury in the rat liver. Shock 2010, 33:306-314.
33. Tanaka N., Sano K., Horiuchi A., et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008, 42:413-418.
34. Capanni M., Calella F., Biagini M.R., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006, 23:1143-1151.
35. 1H MR spectroscopy. Radiology 2010, 256:159-168.